ClinicalTrials.gg
RecruitingNCT01873924Updated Nov 4, 2026

Clinical and Neuropsychological Investigations in Batten Disease

An observational study in Neuronal Ceroid Lipofuscinosis, Neuronal Ceroid Lipofuscinosis CLN1 and Neuronal Ceroid Lipofuscinosis CLN2, sponsored by University of Rochester. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Rochester · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States — 10 open to participants now, 18 under way, none of them phase 3. Neuronal Ceroid-Lipofuscinoses · United States.

Planned enrollment
7th of 18
500 · median 65
Started
2004
with 1 other
Observational
18 of 38
8 open now
Primary completion
2035-08
later than 13 of 17 live
Registered
14th of 38
by date
Lead sponsor
2 of 38
University of Rochester

Among the 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2004, is one of 18 observational ones, reaches primary completion later than 13 of the 17 other live ones, and was the 14th registered.

Neuronal Ceroid-Lipofuscinoses

49 studies on the registry are indexed under Neuronal Ceroid-Lipofuscinoses; 13 are open to participants now.

Browse Neuronal Ceroid-Lipofuscinoses studies →

Open to participants now

10 of the 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Neuronal Ceroid-Lipofuscinoses studies recruiting now, 7 (64%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States, or all of them as a file.
02

Study summary

This study aims to assess the natural history of Batten disease (Neuronal Ceroid Lipofuscinosis) by obtaining information about the motor, behavioral, and functional capabilities of individuals with Batten disease. This study will also refine and validate the Unified Batten Disease Rating Scale (UBDRS) as a clinical rating instrument for Batten disease.

Read the detailed description

Batten Disease is an inherited disorder that causes progressive cognitive and behavioral decline in children. There have been no systematic clinical studies of Batten Disease using standardized rating instruments with known inter-rater reliability and validity.

The Batten Study Group developed the Unified Batten Disease Rating Scale (UBDRS), a clinical rating instrument used to assess the motor, behavioral, and functional capabilities of individuals with Batten disease. Using the UBDRS, study investigators will evaluate participants approximately every year to track disease progression. The UBDRS is the primary natural history tool, but the study also includes neuropsychological assessment, adaptive function, quality of life measures, and other measures to assess the impact of Batten Disease. Participants will be examined at the University of Rochester Batten Center, Batten Disease Support and Research Association annual meeting, or remotely via televideo. Information related to racial and ethnic background, medical history, symptoms, medications, and diagnostic testing will be collected.

03

Conditions studied

  • Neuronal Ceroid Lipofuscinosis
  • Neuronal Ceroid Lipofuscinosis CLN1
  • Neuronal Ceroid Lipofuscinosis CLN2
  • Neuronal Ceroid Lipofuscinosis CLN3
  • Neuronal Ceroid Lipofuscinosis CLN5
  • Neuronal Ceroid Lipofuscinosis CLN6
  • Neuronal Ceroid Lipofuscinosis CLN7
  • Neuronal Ceroid Lipofuscinosis CLN8
  • Neuronal Ceroid Lipofuscinosis CLN10
  • Batten Disease

Keywords

  • Batten disease
  • NCL
  • Neuronal Ceroid Lipofuscinosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals diagnosed with any form of Batten disease and their parents/legal guardians are eligible to take part in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • child or adult with any form of Batten disease
  • parent or legal guardian of a child or adult with any form of Batten disease

Exclusion criteria

Exclusion Criteria:

- parent or guardian unable or unwilling to provide permission for the affected individual

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Batten disease

    Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)

06

What researchers measure

Primary outcomes

  1. Unified Batten Disease Rating Scale (UBDRS), assessing the severity and change in physical, seizure, behavioral, and functional aspects of individuals with Batten Disease.

    A quantitative measure of natural history

    Time frame: Annual Assessments for up to 20 years

Secondary outcomes

  1. Cognitive and neurobehavioral functioning of individuals with Batten disease

    A standardized battery of neuropsychological tests and neurobehavioral assessments will be used to measure cognitive skills (e.g., verbal reasoning, attention, memory, language), mood, behavior, adaptive function, and quality of life.

    Time frame: Annual Assessments for up to 10 years

  2. Quantitative assessment of vision and retinal thickness

    Vision and retinal thickness assessments include visual acuity, visual fields, fundus photography to document anatomic extent of disease, fundus autofluorescence to measure lipofuscin accumulation, and optical coherence tomography (OCT) to provide detailed images of retinal structure, measure retinal layers, and measure central macular thickness.

    Time frame: Annual Assessments for up to 20 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Aug 2035 and a completion of Aug 2035. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2013
First posted
Jun 10, 2013
Start
Aug 2004
Primary completionEst.
Aug 2035
CompletionEst.
Aug 2035
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01873924
Responsible party
Jennifer Vermilion (Assistant Professor, University of Rochester) — Principal investigator
First posted
Jun 10, 2013
Start date
Aug 2004
Primary completion
Aug 2035 (estimated)
Completion
Aug 2035 (estimated)
Last update
Nov 4, 2026

Study contacts

Amy Vierhile, RN PNP
Contact
amy_vierhile@urmc.rochester.edu
(585)275-4762
Jonathan W Mink, MD PhD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion